Search

Your search keyword '"Tartour E"' showing total 523 results
Start Over Author "Tartour E"
523 results on '"Tartour E"'

5. 180P Immunogenomic profiling of the randomized NeoPembrOv clinical trial reveals the VEGFR2 angiogenic axis as a promising actionable target to overcome immunoresistance of high-grade ovarian carcinomas

Author

Le Saux, O., primary, Ardin, M., additional, Berthet, J., additional, Bourhis, M., additional, Treilleux, I., additional, Just, P-A., additional, Bataillon, G., additional, Savoye, A.M., additional, Mouret-Reynier, M-A., additional, Coquan, E., additional, Derbel, O., additional, Bouizaguen, S., additional, Labidi-Galy, S.I., additional, Tartour, E., additional, Galy-Fauroux, I., additional, Stern, M-H., additional, Terme, M., additional, Caux, C., additional, Dubois, B., additional, and Ray-Coquard, I.L., additional

Published
2023
Full Text
View/download PDF

8. Prognostic Significance of the Microenvironment in Human Papillomavirus Oropharyngeal Carcinoma: A Systematic Review.

Author

Baudouin, R., Hans, S., Lisan, Q., Morin, B., Adimi, Y., Martin, J., Lechien, J. R., Tartour, E., and Badoual, C.

Abstract

Objective: The immune microenvironment of HPV‐associated (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) (HPV+OPSCCs) differs from that of HPV‐independent oropharyngeal cancers (HPV‐independent OPSCCs). The literature on the subject is very abundant, demanding an organized synthesis of this wealth of information to evaluate the hypothesis associating the favorable prognosis of HPV+OPSCC patients with a different immune microenvironment. A systematic review of the literature was conducted regarding the microenvironment of HPV+OPSCCs. Data Source: MEDLINE/PubMed, Embase, and Cochrane Library databases. Review Methods: A literature search was performed following PRISMA guidelines (Moher D. PLoS Med. 2009). The PEO (Population, Exposure, and Outcome) framework is detailed as follows: P: patients with oropharyngeal squamous cell carcinomas, E: human papillomavirus (HPV), and O: histological and immunological composition of the tumoral microenvironment (TME). No meta‐analysis was performed. Results: From 1,202 studies that were screened, 58 studies were included (n = 6,474 patients; n = 3,581 (55%) HPV+OPSCCs and n = 2,861(45%) HPV‐independent OPSCCs). The presence of tumor‐infiltrating lymphocytes (TIL), CD3+ in 1,733 patients, CD4+ in 520 patients, and CD8+ (cytotoxic T lymphocytes (CTL)) in 3,104 patients, and high levels of PD‐L1 expression in 1,222 patients is strongly correlated with an improved clinical outcome in HPV+OPSCCs. Conclusion: This systematic review provides the most comprehensive information on the immune microenvironment of HPV+OPSCCs to date. Tumor‐infiltrating lymphocytes and PD‐L1 expression are associated with a favorable prognosis. B, CD8+ and resident memory cells densities are higher in HPV+OPSCCs. The importance of myeloid lineages is still a matter of debate and research. Level of Evidence: NA Laryngoscope, 134:1507–1516, 2024 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial

Author

Ouedraogo, E., Sanou, G., Gueguen, S., Lopez Perez, E., Ammour, K., Kocken, C., Batteux, F., Tartour, E., Sirima, S.B., Durier, C., Kara, L., Houard, S., Gansane, A., Loulergue, P., Bahuaud, M., Benhamouda, N., Nebié, I., Faber, B., Remarque, E., and Launay, O.

Published
2017
Full Text
View/download PDF

11. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

Author

Daban, A, primary, Gonnin, C, additional, Phan, L, additional, Saldmann, A, additional, Granier, C, additional, Lillo-Lelouet, A, additional, Le Beller, C, additional, Pouchot, J, additional, Weiss, l, additional, Tartour, E, additional, Fabre, E, additional, Medioni, J, additional, Oudard, S, additional, Vano, YA, additional, Dragon-Durey, MA, additional, and Simonaggio, A., additional

Published
2023
Full Text
View/download PDF

12. CO8.1 - Challenges inhérents à la mise en place d'une cohorte vaccinale COVID-19 pour les populations particulières en temps de crise: la cohorte ANRS0001S COV-POPART

Author

Gilbert, C., primary, Longobardi, J., additional, Barquin, A., additional, Kali, S., additional, Mestre, S. Le, additional, Circosta, S., additional, Parfait, B., additional, Pellegrin, I., additional, Brassart, C., additional, Gillet, S., additional, Merchadou, L., additional, Tartour, E., additional, De Lamballerie, X., additional, Loubet, P., additional, Launay, O., additional, and Wittkop, L., additional

Published
2023
Full Text
View/download PDF

19. P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer

Author

Benhamouda, N, primary, Sam, I, additional, Epaillard, N, additional, Gey, A, additional, Saldmann, A, additional, Pineau, J, additional, Hasan, M, additional, Verkarre, V, additional, Libri, V, additional, Mella, S, additional, Granier, C, additional, Broudin, C, additional, Ravel, P, additional, Jabla, B, additional, Chaput, N, additional, Albiges, L, additional, Vano, Y, additional, Adotevi, O, additional, Oudard, S, additional, and Tartour, E, additional

Published
2021
Full Text
View/download PDF

24. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Author

SIRIMA, S. B., Richert, Laura, Chene, A., KONATE, A. T., CAMPION, Cecilia, Dechavanne, S., SEMBLAT, J. P., BENHAMOUDA, N., BAHUAUD, M., Loulergue, P., NEBIE, I., Kabore, M., KARGOUGOU, D., Barry, A., OUATTARA, S. M., BOILET, Valerie, Allais, Florence, Roguet, G., HAVELANGE, N., LOPEZ-PEREZ, E., KUPPERS, A., KONATE, E., Roussillon, Caroline, KANTE, Myriam, BELARBI, L., DIARRA, A., Henry, N., SOULAMA, I., Ouedraogo, A., Esperou, H., Leroy, O., Batteux, F., TARTOUR, E., VIEBIG, N. K., THIEBAUT, Rodolphe, Launay, O., Gamain, B., Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Epidémiologie et Biostatistique [Bordeaux], and Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
parasitic diseases, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, SISTM
Abstract

International audience; BackgroundPRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant.MethodsThis first-in-human, randomised, double-blind, placebo-controlled, dose escalation trial was done in two staggered phases, a phase 1A trial in 18–35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso. Volunteers were recruited into four sequential cohorts receiving PRIMVAC intramuscularly at day 0, 28, and 56: two cohorts in France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC. Volunteers were randomly assigned (1:1) to two groups (PRIMVAC adjuvanted with either Alhydrogel or GLA-SE) in France and randomly assigned (2:2:1) to three groups (PRIMVAC adjuvanted with either Alhydrogel, GLA-SE, or placebo) in Burkina Faso. Randomisation was centralised, using stratification by cohort and blocks of variable size, and syringes were masked by opaque labels. The primary endpoint was the proportion of participants with any grade 3 or higher adverse reaction to vaccination up until day 35. Safety at later time points as well as humoral and cellular immunogenicity were assessed in secondary endpoints. This trial is registered with ClinicalTrials.gov, NCT02658253.FindingsBetween April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included. No serious adverse event related to the vaccine occurred. PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57). PRIMVAC antibody titres reached a peak (geometric mean 11 843·0, optical density [OD] 1·0, 95% CI 7559·8–18 552·9 with 100 μg dose and GLA-SE) 1 week after the third vaccination (day 63). Compared with Alhydrogel, GLA-SE tended to improve the PRIMVAC antibody response (geometric mean 2163·5, OD 1·0, 95% CI 1315·7–3557·7 with 100 μg dose and Alhydrogel at day 63). 1 year after the last vaccination, 20 (71%) of 28 women who were vaccinated with PRIMVAC/Alhydrogel and 26 (93%) of 28 women who were vaccinated with PRIMVAC/GLA-SE still had anti-PRIMVAC antibodies, although antibody magnitude was markedly lower (452·4, OD 1·0, 95% CI 321·8–636·1 with 100 μg dose and GLA-SE). These antibodies reacted with native homologous VAR2CSA expressed by NF54-CSA infected erythrocytes (fold change from baseline at day 63 with 100 μg dose and GLA-SE: 10·74, 95% CI 8·36–13·79). Limited cross-recognition, restricted to sera collected from women that received the 100 μg PRIMVAC dose, was observed against heterologous VAR2CSA variants expressed by FCR3-CSA (fold change from baseline at day 63: 1·49, 95% CI 1·19–1·88) and 7G8-CSA infected erythrocytes (1·2, 1·08–1·34).InterpretationPRIMVAC adjuvanted with Alhydrogel or GLA-SE had an acceptable safety profile, was immunogenic, and induced functional antibodies reacting with the homologous VAR2CSA variant expressed by NF54-CSA infected erythrocytes. Cross-reactivity against heterologous VAR2CSA variants was limited and only observed in the higher dose group. An alternate schedule of immunisation, antigen dose, and combinations with other VAR2CSA-based vaccines are envisaged to improve the cross-reactivity against heterologous VAR2CSA variants.FundingBundesministerium für Bildung und Forschung, through Kreditanstalt für Wiederaufbau, Germany; Inserm, and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland.

Published
2020

26. Les auteurs

Author

Adotévi., O., Amé-Thomas., P., Arnulf., B., Baron., C., Batteux., F., Beauvillain., C., Bérard., F., Blancho., G., Bourdenet., G., Boyer., O., Caillat-Zucman., S., Candon., S., Carapito., R., Carcelain., G., Carnoy., C., Cesbron., J.-Y., Chevailler., A., Chollet-Martin., S., Colombo., B., Contin-Bordes., C., Coutant., F., Dantal., J., de Carvalho Bittencourt., M., de Chaisemartin., L., Delfau-Larue., M.-H., Desplat-Jégo., S., Dragon-Durey., M.-A., Dubucquoi., S., Dumestre-Perard., C., Fischer., A., Fisson., S., Flament., H., Fournel., S., Galaine., J., Garraud., O., Godet., Y., Gorochov., G., Gros., F., Gubler., B., Guffroy., A., Hacein-Bey-Abina., S., Hoarau., C., Hüe., S., Kaplanski., G., Kervella., D., Kolopp Sarda., M.-N., Labalette., M., Lambotte., O., Le Gouvello., S., Le Naour., R., Lelièvre., J.-D., Lemoine., F., Liégeois., S., Martinet., J., Miyara., M., Moins-Teisserenc., H., Molinier-Frenkel., V., Nel., I., Pagès., F., Paul., S., Picard., C., Radosavljevic., M., Renaudineau., Y., Rosain., J., Rosenzwajg., M., Seillès., E., Soulas-Sprauel., P., Sterlin., D., Tartour., É., Taupin., J.-L., Thibault., G., Tiberghien., P., Toubert., A., Visentin., J., Vitte., J., Vivier., É., Watier., H., and Weiss., L.

Published
2023
Full Text
View/download PDF

30. Cxcr6-deficiency impairs cancer vaccine efficacy and resident memory CD8+ T-cells recruitment in tumor

Author

Karaki, S, Blanc, C, Tran, T, Galy-Fauroux, I, Anson, M, Golub, R, Tartour, E, Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Immunization route is directly correlated with cancer vaccine efficacy. Our team previously showed that mucosal (intranasal, i.n.) and systemic (intramuscular) vaccinations are both able to induce systemic specific CD8+ T-cells but only i.n. immunization allows an efficient control of mucosal tumor growth. Indeed, the i.n. vaccination favors the tumor infiltration of specific CD8+ T-cells and especially tissue-resident memory T-cells (Trm), which are crucial for a potent antitumor activity. Based on a transcriptomic analysis, we have identified a chemokine receptor, CXCR6, highly expressed by these specific Trm CD8+ T-cells, induced by the i.n. vaccination. To understand the role of CXCR6 in vaccination efficacy, we have set up a body of experiments using heterozygous Cxcr6gfp/+ mice, where GFP reflects CXCR6 expression and homozygous Cxcr6-deficient mice Cxcr6gfp/gfp.We have then confirmed CXCR6 expression on specific Trm CD8+ T-cells induced by i.n. vaccination in lung mucosa. Using an orthotopic head and neck tumor model, CXCR6 expression on tumor-infiltrating Trm induced by i.n. immunization has also been reported. In addition, we showed that Cxcr6-deficiency impairs mice survival in a prophylactic and therapeutic i.n. vaccination settings in various mucosal tumor models. In this Cxcr6-deficient mouse model, the loss of vaccine-induced protection against tumor graft correlates with a clear reduction of Trm infiltration in tumor. Finally, in a cohort of human lung cancer, we have observed endogenous CXCR6+ Trm infiltrating these tumors in situ. To conclude, we have identified CXCR6 as a required parameter to recruit the crucial anti-tumor Trm in mucosal tumor. Our results finally indicate that CXCR6 might be a new surrogate biomarker to evaluate antitumor vaccine efficacy.

Published
2018

31. Neutrophil to lymphocyte ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N)

Author

Simonaggio, A., primary, Elaidi, R., additional, Fournier, L., additional, Fabre, E., additional, Ferrari, V., additional, Borchiellini, D., additional, Thibault, C., additional, Barthelemy, P., additional, Thouvenin, J., additional, Tartour, E., additional, Oudard, S., additional, and Vano, Y., additional

Published
2019
Full Text
View/download PDF

33. Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)

Author

Marabelle, A., primary, Ghiringhelli, F., additional, Ayyoub, M., additional, Tartour, E., additional, Adotevi, O., additional, Loriot, Y., additional, Lambotte, O., additional, Cupissol, D., additional, Damotte, D., additional, Adam, J., additional, Bonvalet, M., additional, Petre Lazar, B., additional, Licour, M., additional, and Chaput, N., additional

Published
2018
Full Text
View/download PDF

36. Current events in immunotherapy for upper aerodigestive tract cancer

Author

Outh-Gauer , S, Le Tourneau , C, Broudin , C, Scotte , F, Roussel , H, Hans , Stéphane, Mandavit , M, Tartour , E, Badoual , Cécile, Cancer et génôme: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, MINES ParisTech - École nationale supérieure des mines de Paris-Institut Curie-Institut National de la Santé et de la Recherche Médicale (INSERM), LPP - Laboratoire de Phonétique et Phonologie - UMR 7018 (LPP), Université Sorbonne Nouvelle - Paris 3-Centre National de la Recherche Scientifique (CNRS), Service d'oto-rhino-laryngologie et chirurgie cervico-faciale [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service d'anatomo-pathologie [CHU HEGP], Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, Institut Curie [Paris]-MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), MINES ParisTech - École nationale supérieure des mines de Paris-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -INSTITUT CURIE, LPP - Laboratoire de Phonétique et Phonologie - UMR 7018 ( LPP ), Université Sorbonne Nouvelle - Paris 3-Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Cytokines et Immunologie des Tumeurs Humaines ( U753 ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut Gustave Roussy ( IGR ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Européen Georges Pompidou [APHP] ( HEGP )

Subjects
PD-L1, HPV, Cancers des voies aérodigestives supérieures, Immunothérapie, PD-1, [ SHS.LANGUE ] Humanities and Social Sciences/Linguistics, Immunotherapy, [SHS.LANGUE]Humanities and Social Sciences/Linguistics, Head and neck cancer, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

40. Pre-existing antitumor CD4 Th1 immunity in blood and PD-1/TIM-3+ CD4 T cells predict distinct outcome in lung cancer

Author

Dosset, M., primary, Laheurte, C., additional, Vernerey, D., additional, Lauret Marie Joseph, E., additional, Rangan, L., additional, Fabre, E., additional, Le Pimpec-Barthes, F., additional, Tartour, E., additional, Eberst, G., additional, Kaulek, V., additional, Jacquin, M., additional, Westeel, V., additional, Borg, C., additional, Godet, Y., additional, and Adotevi, O., additional

Published
2017
Full Text
View/download PDF

41. A LOW BASELINE BLOOD NEUTROPHIL COUNT AND A HIGH PERCENTAGE OF TREG AMONG LEUCOCYTES ARE ASSOCIATED WITH AN INCREASED OVERALL SURVIVAL OF RECURRENT HIGH-GRADE GLIOMA PATIENTS TREATED WITH BEVACIZUMAB

Author

Quillien, V., Carpentier, A., Gey, A., Avril, T., Tartour, E., Sejalon, F., Campillo-Gimenez, B., Vauléon, E., CRLCC Eugène Marquis (CRLCC), Oncogenesis Stress Signaling (OSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CRLCC Eugène Marquis ( CRLCC ), Oncogenesis Stress Signaling ( OSS ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -CRLCC Eugène Marquis ( CRLCC ), Paris-Centre de Recherche Cardiovasculaire ( PARCC - U970 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer, [ SDV.CAN ] Life Sciences [q-bio]/Cancer
Abstract

International audience; Conference: 12th Meeting of the European-Association-of-Neuro-Oncology Location: GERMANY Date: OCT 12-16, 2016 - Meeting Abstract: P06.13

Published
2016

42. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial

Author

Sirima, S.B., primary, Durier, C., additional, Kara, L., additional, Houard, S., additional, Gansane, A., additional, Loulergue, P., additional, Bahuaud, M., additional, Benhamouda, N., additional, Nebié, I., additional, Faber, B., additional, Remarque, E., additional, Launay, O., additional, Ouedraogo, E., additional, Sanou, G., additional, Gueguen, S., additional, Lopez Perez, E., additional, Ammour, K., additional, Kocken, C., additional, Batteux, F., additional, and Tartour, E., additional

Published
2017
Full Text
View/download PDF

50. Combinaison of an anti HPV-E7 vaccine to radiotherapy: preclinical data in a head and neck model

Author

Mondini, M., primary, Nizard, M., additional, Tran, T., additional, Mauge, L., additional, Loi, M., additional, Clémenson, C., additional, Dugue, D., additional, Maroun, P., additional, Louvet, E., additional, Adam, J., additional, Badoual, C., additional, Helley, D., additional, Dransart, E., additional, Johannes, L., additional, Vozenin, M.C., additional, Perfettini, J.L., additional, Tartour, E., additional, and Deutsch, E., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results